The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management, Cancer Cell International
Frontiers HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
POR Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
Cells, Free Full-Text
Pathologic Assessment and Staging of Multiple Non–Small Cell Lung Carcinomas: A Paradigm Shift with the Emerging Role of Molecular Methods - Modern Pathology
PDF) Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
Biomarker Tests LUNGevity Foundation
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Cancers, Free Full-Text
PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Cancers, Free Full-Text
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
